Atuka (Canada)

The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease

James B. Koprich, Susan H. Fox, Tom H. Johnston et al. · Movement Disorders · 2011 · 68 citations

Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit

Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas et al. · Movement Disorders · 2013 · 67 citations · Full text

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque

James B. Koprich, Tom H. Johnston, Gabriela Reyes et al. · PLoS ONE · 2016 · 61 citations · Full text

Neurogenomics, Non-human Primate Model, Neurochemical Biomarkers +22

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque

Tom H. Johnston, Philippe Huot, Susan H. Fox et al. · Neuropharmacology · 2013 · 38 citations

Neurophysiology, Medicine, Neuropharmacology +9

Pridopidine, a clinic‐ready compound, reduces 3,4‐dihydroxyphenylalanine‐induced dyskinesia in Parkinsonian macaques

Tom H. Johnston, Michal Geva, Lilach Steiner et al. · Movement Disorders · 2018 · 37 citations